Effects of Primary Tumor Resection on the Survival of Patients with Stage IV Extrathoracic Metastatic Non-Small Cell Lung Cancer: A Population-Based Study

Lung cancer is the leading cause of cancer-related death worldwide. Based on the updated Surveillance, Epidemiology, and End Results (SEER) data, up to 55% of all patients with newly diagnosed lung cancer have advanced disease with extrathoracic metastases. Systemic therapy is the main therapeutic strategy for patients with stage IV lung cancer [1]. Yet, the 5-year overall survival (OS) rate for patients with distant metastatic disease still remains extremely low (2%). Local consolidative therapy based multidisciplinary management, other than palliative treatment for relieving localized symptoms, has been attempted to improve the long-term outcome for selected patients with distant metastases.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research